AIDS Controversy Alive As Before; This Time, Phase III Data And Race
Talk about a hard call.
Investors may have been quick to attach their unmistakable meaning to last month's disclosure by VaxGen Inc. of disappointing Phase III results for its HIV vaccine - the company's stock value nosedived by 47.3 percent - but the scientific world was far from convinced a disaster had taken place.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter